Full Breakdown
Elevance Health Q3 2026 Results: Guidance Lift and Analyst Target Upgrade
By Drooid · · How we work
Core Event – Q3 2026 Earnings and Guidance
Elevance Health reported third-quarter 2026 operating revenue of $50.4 billion and shareholders’ net income of $1.365 billion, yielding a diluted EPS of $6.27 and an adjusted diluted EPS of $6.99. Management raised full-year 2026 diluted EPS guidance to at least $22.00 and adjusted diluted EPS to at least $29.00, and increased operating cash-flow guidance to at least $6.5 billion.
Background & Context – Prior Quarter and Market Expectations
In the second quarter ended June 30 2026, Elevance Health posted revenue of $49.83 billion and earnings per share of $7.45, surpassing a consensus estimate of $6.21. Analysts had anticipated a 2.3 percent year-over-year revenue decline for the third quarter (FinancialContent preview). The company’s performance was therefore viewed against expectations of modest contraction.
Data & Statistics – Key Financial Metrics
- Operating revenue (Q3 2026): $50.4 billion vs. $49.83 billion reported by other outlets (The Globe and Mail, Ad-hoc News).
- Operating margin: 2.5 percent (adjusted 2.7 percent).
- Benefit expense ratio: 90.6 percent, a 70-basis-point improvement year-over-year.
- Operating expense ratio: 11.4 percent (adjusted 11.3 percent).
- Cash and cash equivalents: $10.348 billion as of Sept. 30 2026.
- Medical membership: approximately 44 million members.
- Share repurchase: 0.8 million shares for $330 million in Q3.
- Quarterly dividend: $1.72 per share payable December 18 2026.
Official Statements & Responses – Company Commentary
The company also noted that the dividend and share-repurchase program reflect confidence in cash generation.
Analyst Action – Guggenheim Target Increase
On October 12 2026, Guggenheim lifted its price target for Elevance Health from $455.00 to $460.00, maintaining a Buy rating (Ad-hoc News, MarketScreener). This target sits 4.5 percent above the NYSE closing price of $440.18 on October 20 2026 and $8.29 above the consensus analyst target of $451.71.
Market Reaction – Stock Prices in Euros and Dollars
The stock traded at €389.00 on October 20 2026, representing a 1.89 percent premium to the Xetra close of that day. On October 21 2026, the same price of €389.00 was recorded at 11:39 a.m. CEST. In U.S. dollars, the NYSE price was $436.08 at 10:32 a.m. EDT on October 20 2026, placing the share price 0.25 percent below its recent high.
Conflicting Reports & Gaps – Revenue Figure Discrepancies
Sources differ on the exact third-quarter revenue figure. TradingView’s filing lists $50.4 billion, while The Globe and Mail and Ad-hoc News cite $49.83 billion, describing it as “flat year-on-year.” Both figures are presented as company-reported numbers, but the discrepancy is not resolved within the available reports.
Timeline – Chronology of Recent Milestones
- July 15 2026: Q2 earnings released – $7.45 EPS and $49.83 billion revenue.
- June 30 2026: Second-quarter revenue of $49.83 billion confirmed.
- October 12 2026: Guggenheim raises target to $460.00.
- October 20 2026: NYSE close $440.18; Euro price €389.00, 1.89 % above Xetra close.
- October 21 2026: Q3 results released before market open; conference call scheduled for 8:30 a.m. EDT.
- December 18 2026: Quarterly dividend of $1.72 per share payable.
The combined data illustrate Elevance Health’s effort to sustain revenue growth, improve margins, and deliver higher shareholder returns while navigating analyst expectations and modest market fluctuations.